Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which
selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2. The
purpose of this study is to studying neoadjuvant JS001, or JS001 in combination with
pemetrexed and carboplatin to see how well it works in treating patients with resectable
NSCLC.